Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma
Abdominal Radiology · 2024
DOI: 10.1007/s00261-024-04661-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Abdominal Radiology, 2024. Verfasst von Qiupng Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Magnetic Resonance Imaging, Tomography, X-Ray Computed. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Key Research and Development Program of Shanxi Province, Special program of sustainable development of the Science, Technology and Innovation Commission of Shenzhen Municipality, The National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND & AIMS: The current staging system has limitations in preoperatively assessing hepatocellular carcinoma (HCC) and in precise detailed treatment allocation. This study aims to propose a new Liver Tumor Imaging Staging (LTIS) method for HCC. METHODS: 1295 patients who underwent CT or MRI and curative liver resection during January 2012 and October 2020 were retrospectively recruited from three independent institutions. All images were interpreted by two abdominal and a board-certified radiologist. LTIS was designed to discriminate low-grade (absence of microvascular invasion [MVI] and Edmondson-Steiner grade III/IV), intermediate (MVI + or Edmondson-Steiner grade III/IV but not both) and high-grade HCC (MVI + and Edmondson-Steiner grade III/IV) upon CT and MRI. Model was constructed in 578 derivation cohort (center 1) and validated in internal center 1 test cohort (n = 291), and external center 2 (n = 226) and center 3 (n = 200), respectively. Cronbach's alpha statistics were determined to assess interobserver agreement. Net clinical benefit of LTIS on recurrence-free survival (RFS) and overall survival (OS) was analyzed with a Cox proportional hazards model. RESULTS: LTIS shows good inter-reader agreements in both CT and MRI datasets, with a Cronbach's alpha coefficient of 0.86 and 0.85, respectively. In independent test, LTIS achieved agreement of 73.2% (281/384), 18.9% (100/528), and 69.2% (265/383) for determining low, intermediate, and high-grade HCCs with "ground truth" results. In the Cox analysis, LTIS was comparable to "ground truth" grade for predicting RFS (hazards ratio (HR), 1.30 vs. ground truth grade, 1.36 and 1.56) and OS (HR, 1.76 vs. ground truth grade, 2.00 and 3.03) of patients after surgery. In patients conventionally classified as having low-grade tumors (serum α-fetoprotein < 400 ng/mL, stage T1), 47.4% and 35.6% were reclassified as high-grade tumors upon LTIS restaging. The resulting LTIS subgroups showed a significant difference in RFS and OS at Kaplan-Meier analysis (Log-rank test, p < 0.001). CONCLUSION: LTIS provides a potential noninvasive way to precisely stage HCC using CT and MRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
- Department of Radiology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Radiology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- Department of Radiology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- PLA General Hospital, Beijing, China.
- Guangdong Key Laboratory of Epigenetics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China.
Förderung
- the Key Research and Development Program of Shanxi Province
- Special program of sustainable development of the Science, Technology and Innovation Commission of Shenzhen Municipality
- The National Natural Science Foundation of China
Zitieren
APA
Liu, Q., Li, X., Yang, K., Sun, S., Xu, X., Qu, K., Xiao, J., Liu, C., Yu, H., Lu, Y., Qu, J., Zhang, Y., & Zhang, Y. (2024). Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04661-6
Vancouver
Liu Q, Li X, Yang K, Sun S, Xu X, Qu K, et al. Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma. Abdominal Radiology. 2024. doi:10.1007/s00261-024-04661-6
BibTeX
@article{Liu2024,
author = {Liu, Qiupng and Li, Xiang and Yang, KaiLan and Sun, ShuWen and Xu, Xun and Qu, Kai and Xiao, Jiaqi and Liu, Chenyue and Yu, HangQi and Lu, YinYing and Qu, JinRong and Zhang, YuDong and Zhang, Yuelang},
title = {Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma},
journal = {Abdominal Radiology},
year = {2024},
doi = {10.1007/s00261-024-04661-6}
}
EUVIMED